For example, grade 3-4 infection occurred in only 16-22% of patients who received talquetamab in MonumenTAL-1 (26% in the cohort with prior anti-BCMA therapy), but 52% and 40.7% of patients treated with teclistamab and elranatamab, respectively (80, 81, 146, 155). Here, TNFRSF17 is linked to infection.